Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Subcutaneous panniculitis-like T-cell lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1

Interventions

Rituximab 173Cyclophosphamide 156Vincristine 72fludarabine phosphate 71Etoposide 68Doxorubicin 68Prednisone 66Filgrastim 58Methotrexate 52Cytarabine 51fludarabine 49Melphalan 48Busulfan 47Tacrolimus 41Whole-Body Irradiation 39Mycophenolic Acid 39Granulocyte Colony-Stimulating Factor 37Antilymphocyte Serum 31Peripheral Blood Stem Cell Transplantation 30Radiotherapy 27Lenalidomide 25Dexamethasone 25Carmustine 23Stem Cell Transplantation 22Cyclosporine 22Bortezomib 22Gemcitabine 20Bendamustine Hydrochloride 20ibritumomab tiuxetan 19Alemtuzumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma × siplizumab × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡